Abstract
Over the past decade therapeutic interventions during pregnancy, including the use of drugs, has increased; for example, the prescription use of opioids and nonopioid analgesics for pain management during pregnancy has increased by about 40%. Additionally, women also self-medicate during pregnancy with opioids, and are treated with methadone and buprenorphine which are used as substitution therapy for substance dependence during pregnancy. A nationally representative survey noted that ∼74% of women of reproductive age reported substance use during the previous year, decreasing to ∼ 63% amongst those who were pregnant. Substance dependence was reported by ∼ 20% of women who were not pregnant, and ∼ 15% of those who were pregnant. Understanding the consequences of opioid treatment or dependence during pregnancy requires an investigation of the placental disposition (metabolism and transfer), as well as of the impact of the drugs on the placental function. This review summarizes the research on the placental disposition of opioids and their impact on the placental function.
Keywords: Analgesics, drug abuse, drugs in pregnancy, drug transfer, ex vivo perfusion model, human placenta, narcotics, opioids, substitution therapy, placental disposition
Current Pharmaceutical Biotechnology
Title: Drugs and Medicines in Pregnancy: The Placental Disposition of Opioids
Volume: 12 Issue: 5
Author(s): Antoine Malek and Donald R. Mattison
Affiliation:
Keywords: Analgesics, drug abuse, drugs in pregnancy, drug transfer, ex vivo perfusion model, human placenta, narcotics, opioids, substitution therapy, placental disposition
Abstract: Over the past decade therapeutic interventions during pregnancy, including the use of drugs, has increased; for example, the prescription use of opioids and nonopioid analgesics for pain management during pregnancy has increased by about 40%. Additionally, women also self-medicate during pregnancy with opioids, and are treated with methadone and buprenorphine which are used as substitution therapy for substance dependence during pregnancy. A nationally representative survey noted that ∼74% of women of reproductive age reported substance use during the previous year, decreasing to ∼ 63% amongst those who were pregnant. Substance dependence was reported by ∼ 20% of women who were not pregnant, and ∼ 15% of those who were pregnant. Understanding the consequences of opioid treatment or dependence during pregnancy requires an investigation of the placental disposition (metabolism and transfer), as well as of the impact of the drugs on the placental function. This review summarizes the research on the placental disposition of opioids and their impact on the placental function.
Export Options
About this article
Cite this article as:
Malek Antoine and R. Mattison Donald, Drugs and Medicines in Pregnancy: The Placental Disposition of Opioids, Current Pharmaceutical Biotechnology 2011; 12 (5) . https://dx.doi.org/10.2174/138920111795470859
DOI https://dx.doi.org/10.2174/138920111795470859 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Metabolic Acidosis in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Signature of HPV-Induced Carcinogenesis: pRb, p53 and Gene Expression Profiling
Current Genomics Extra-telomeric Functions of Human Telomerase: Cancer, Mitochondria and Oxidative Stress
Current Pharmaceutical Design In-Silico Algorithms for the Screening of Possible microRNA Binding Sites and Their Interactions
Current Genomics Modern Pathology: Protein Mis-Folding and Mis-Processing in Complex Disease
Current Protein & Peptide Science Taking Risk Prediction to the Next Level. Advances in Biomarker Research for Atherosclerosis
Current Pharmaceutical Design Peptides Targeting Estrogen Receptor Alpha-Potential Applications for Breast Cancer Treatment
Current Pharmaceutical Design Nitrone Derivatives as Therapeutics: From Chemical Modification to Specific-targeting
Current Topics in Medicinal Chemistry Targeting Cytokines as an Approach to Modulate Allergic Diseases: The Clinical Experience
Medicinal Chemistry Reviews - Online (Discontinued) Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Extracellular Hsp70: Export and Function
Current Protein & Peptide Science Antibodies As Promising Novel Neuroprotective Agents in the Central Nervous System Injuries
Central Nervous System Agents in Medicinal Chemistry Reactive Oxygen Species, Vascular Disease and Cardiovascular Surgery
Current Vascular Pharmacology Integrin Signaling Networks in the Pathobiology of Vascular Smooth Muscle Cells
Vascular Disease Prevention (Discontinued) Epidemiology, Evolution, Transmission, and Therapeutics of COVID-19 Outbreak: An Update on the Status
Coronaviruses Carotenoids of Microalgae Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry MicroRNAs: Modulators of Tooth Development
MicroRNA Accumulation of Intraneuronal Amyloid-β is Common in Normal Brain
Current Alzheimer Research Glutamate and Mitochondria: Two Prominent Players in the Oxidative Stress-Induced Neurodegeneration
Current Alzheimer Research Anti-TNF Treatment in Rheumatoid Arthritis
Current Pharmaceutical Design